Prime Medicine, Inc. (PRME)
Automate Your Wheel Strategy on PRME
With Tiblio's Option Bot, you can configure your own wheel strategy including PRME - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRME
- Rev/Share 0.318
- Book/Share 0.8169
- PB 2.5339
- Debt/Equity 1.1331
- CurrentRatio 4.7762
- ROIC -0.6863
- MktCap 271779512.0
- FreeCF/Share -0.8512
- PFCF -2.4395
- PE -1.3412
- Debt/Assets 0.3692
- DivYield 0
- ROE -1.2505
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PRME | Citigroup | Buy | Neutral | -- | $1.5 | May 27, 2025 |
| Downgrade | PRME | H.C. Wainwright | Buy | Neutral | -- | -- | May 20, 2025 |
| Downgrade | PRME | JP Morgan | Overweight | Neutral | -- | -- | May 20, 2025 |
| Initiation | PRME | JMP Securities | -- | Mkt Outperform | -- | $10 | Dec. 10, 2024 |
News
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
Read More
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
Read More
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago.
Read More
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2025 and provided a business update.
Read More
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D.
Read More
About Prime Medicine, Inc. (PRME)
- IPO Date 2022-10-20
- Website https://www.primemedicine.com
- Industry Biotechnology
- CEO Dr. Jeremy S. Duffield M.D., Ph.D.
- Employees 214